Top Markets
#1 ADO Protocol ADO Protocol +335.42%
#2 GoPlus Security GoPlus Security +41.13%
#3 Starpower Starpower +35.26%
#4 GAIB AID GAIB AID +24.67%
#5 FGRS (Figure Tokenized Stock) FGRS (Figure Tokenized Stock) +24.65%
#6 The Black Bull The Black Bull +15.87%
#7 Nockchain Nockchain +14.43%
#8 Provenance Blockchain Provenance Blockchain +12.81%
#9 Casper Network Casper Network +12.45%
#10 DMT-NAT DMT-NAT +11.83%
Coin of the day
ADO Protocol ADO Protocol
Impostazioni
Lingua
ITALIANO
Valuta
USD
Tema
Eagle Pharmaceuticals, Inc. Eagle Pharmaceuticals, Inc.

Eagle Pharmaceuticals, Inc.

EGRX
Classifica tra le azioni #33348
Eagle Pharmaceuticals, Inc., a pharmaceutical company, focuses on... Eagle Pharmaceuticals, Inc., a pharmaceutical company, focuses on manufacturing, developing and commercializing product candidates to treat diseases of the central nervous system or metabolic critical care, and oncology in the United States. The company’s product portfolio offers RYANODEX for malignant hyperthermia; and BELRAPZO and BENDEKA for chronic lymphocytic leukemia and indolent B-cell non-Hodgkin’s lymphoma. It also produces PEMFEXY, a ready-to-dilute liquid form of pemetrexed injection, indicated in combination with cisplatin for the initial treatment of patients with malignant pleural mesothelioma and non-small cell lung cancer; BARHEMSYS, a selective dopamine-2 (D2) and dopamine-3 (D3) receptor antagonist indicated in adults for prevention of postoperative nausea and vomiting (PONV); BYFAVO, a benzodiazepine indicated for the induction and maintenance of procedural sedation in adults. The company has license and collaboration agreements with Combioxin, SA for the development and commercialization rights to CAL02, an anti-toxin agent in Phase 2 development for the treatment of severe pneumonia in combination with traditional antibacterial drugs; ENA-001 developed by Enalare, an agnostic respiratory stimulant for respiratory depression; EA-114, novel and proprietary formulation of fulvestrant developed for hormone-receptor-positive (HR+) metastatic breast cancer. It has a strategic collaboration with Tyme Technologies, Inc. for the development of SM-88 to treat cancer. Eagle Pharmaceuticals, Inc. was incorporated in 2007 and is headquartered in Woodcliff Lake, New Jersey.
Prezzo delle azioni
$0.595
Ultima sincronizzazione: 2026-08-13
Capitalizzazione di mercato
$7.83M
Variazione (1 giorno)
0.00%
Variazione (1 anno)
-81.41%
Paese
US
Scambia Eagle Pharmaceuticals, Inc. (EGRX)

Categoria

Healthcare
Ricavi di Eagle Pharmaceuticals, Inc. (EGRX)
Ricavi nel Aug 2026 TTM: 0
Secondo gli ultimi rapporti finanziari di Eagle Pharmaceuticals, Inc., i ricavi attuali dell'azienda (TTM) sono pari a 0. Nel 2026, l'azienda ha registrato ricavi di 0 uguale a i ricavi dell'anno 2026, che erano pari a 0. I ricavi rappresentano l'importo totale generato dalla vendita di beni o servizi. A differenza degli utili, le spese non vengono detratte.
Storico dei ricavi per Eagle Pharmaceuticals, Inc. da 2026 a 2026
Ricavi alla fine di ogni anno
Anno Ricavi Cambia
Non abbastanza dati per le date fornite.
Ricavi di aziende simili o concorrenti
Azienda Ricavi Differenza nei ricavi Il paese
MERCK Kommanditgesellschaft auf Aktien MERCK Kommanditgesellschaft auf Aktien
MERCK Kommanditgesellschaft auf Aktien
MER.SW
 - -
DE
Merck KGaA Merck KGaA
Merck KGaA
MRK.DE
 - -
DE
Takeda Pharmaceutical Company Limited Takeda Pharmaceutical Company Limited
Takeda Pharmaceutical Company Limited
4502.T
 - -
JP
Galderma Group AG Galderma Group AG
Galderma Group AG
GALD.SW
 - -
CH
Sun Pharmaceutical Industries Limited Sun Pharmaceutical Industries Limited
Sun Pharmaceutical Industries Limited
SUNPHARMA.NS
 $6.61B -
IN